NEUROBiOGEN

본문 바로가기 주메뉴 바로가기

Comunications

NEUROBIOGEN has been working with an advisory network of researchers and clinical
experts specializing in brain & neurological diseases with long experience.

News

News
Notice

News

Here are news on NEUROBIOGEN (currently in Korean only).

NO	SUBJECT	DATE	VIEW
87	CNR Research "U.S. FDA Pre-IND Application for Dementia and Obesity Treatment Substances".	2023. 10. 04	351
86	CNR Research Signs FDA Pre-IND Contract For Neurobiogen Dementia/Obesity Treatment.	2023. 10. 04	319
85	CNR Research Signs U.S. FDA Pre-IND With NeuroBiogen.	2023. 10. 04	451
84	CNR Research, Neurobiogen U.S. FDA Pre-IND Contract.	2023. 10. 04	331
83	CNR Research Signs U.S. FDA Pre-IND Agreement With NeuroBiogen.	2023. 10. 04	320
82	CNR Research, NeuroBiogen U.S. FDA Pre-IND Contract.	2023. 10. 04	331
81	Neurobiogen U.S. FDA Phase 2 Pre-IND Application.	2023. 10. 04	326
80	CNR Research Applies for New Obesity and Dementia Substances Neurobiogen U.S. FDA Pre-IND.	2023. 10. 04	309
79	CNR Research, Neurobiogen U.S. FDA Pre-IND Contract.	2023. 10. 04	345
78	CNR Research "Neurobiogen Obesity Treatment Applies for FDA Pre-IND".	2023. 10. 04	330

1 2 3 4 5